Vanguard Capital Management
IBO

Vanguard Capital Management’s Impact BioMedical IBO Stock Holding History

Vanguard Capital Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372K Buy
808,689
+100,521
+14% +$59.5K ﹤0.01% 3756
2026
Q1 		$425K Buy
+708,168
New +$354K ﹤0.01% 3701

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Vanguard Capital Management's IBO Position: Q2 2026 in Review

Vanguard Capital Management increased its Impact BioMedical (IBO) stake by 14% in Q2 2026, buying an estimated $59.5K and bringing the position to 808,689 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

Vanguard Capital Management first reported a position in IBO in Q1 2026 and has held it in 2 quarters since. The position peaked at $425K in Q1 2026. 21 funds tracked by Wall St. Rank hold IBO as of Q2 2026.

  • Vanguard Capital Management held 808,689 shares of Impact BioMedical worth $372K as of Q2 2026.
  • Vanguard Capital Management bought 100,521 Impact BioMedical shares in Q2 2026, an estimated $59.5K.
  • Impact BioMedical made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3756 holding.
  • Vanguard Capital Management first reported a position in Impact BioMedical in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Impact BioMedical position peaked at $425K in Q1 2026.
  • 21 funds tracked by Wall St. Rank held Impact BioMedical as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.